APA (7th ed.) Citation

Sharareh Seifi, Babak Salimi, Zahra Esfahani Monfared, Cyrus Sabahi, Hamidreza Kafi, & Adnan Khosravi. (2023). Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: A post-marketing surveillance. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Sharareh Seifi, Babak Salimi, Zahra Esfahani Monfared, Cyrus Sabahi, Hamidreza Kafi, and Adnan Khosravi. Alvopem® (pemetrexed) Safety Assessment in Patients with Non-small Cell Lung Cancer or Malignant Pleural Mesothelioma: A Post-marketing Surveillance. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Sharareh Seifi, et al. Alvopem® (pemetrexed) Safety Assessment in Patients with Non-small Cell Lung Cancer or Malignant Pleural Mesothelioma: A Post-marketing Surveillance. Taylor & Francis Group, 2023.